Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer-Reference-Cited by-同舟云学术

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

Published:2009-06-24 Issue:7 Volume:18 Page:1001-1011
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Madan Ravi A¹,Arlen Philip M¹,Mohebtash Mahsa¹,Hodge James W¹,Gulley James L¹

Affiliation:

1. National Cancer Institute, National Institutes of Health, Center for Cancer Research, Laboratory of Tumor Immunology and Biology, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA ; ;

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1517/13543780902997928

Reference103 articles.

1. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

2. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma

3. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

4. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

5. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary cancer prevention for cancers with no known infectious etiology: Time for a new paradigm;Vaccine;2024-03

2. Tumor-associated antigen targets for novel immune-based strategies in prostate cancer;Journal of Translational Genetics and Genomics;2024-02-06

3. Immunotherapeutic strategies and immunotherapy resistance in prostate cancer;Therapy Resistance in Prostate Cancer;2024

4. Knowledge mapping of immunotherapy in castration-resistant prostate cancer: a bibliometric and visualized study (2003–2022);Frontiers in Urology;2023-10-12

5. A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer;Cancer Drug Resistance;2023-09-25